Picture loading failed.

Pre-Made Vonlerolizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vonlerolizumab (MOXR 0916), a monoclonal antibody targeting the OX40 ligand, was being developed by Genentech as an intravenously administered treatment for solid tumours.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-628-1mg 1mg 3090
GMP-Bios-ab-628-10mg 10mg Inquiry
GMP-Bios-ab-628-100mg 100mg Inquiry
GMP-Bios-ab-628-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vonlerolizumab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody
INN Name Vonlerolizumab
TargetCD134
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure6okn:AB:CB/6ogx:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2017
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours;Urogenital cancer
Development Techna